



Baird Medical Showcases Innovations in Endocrine Care at 2024 Southern Yue Forum

December 30, 2024

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Baird Medical (NASDAQ: BDMD), a leading innovator in minimally invasive microwave ablation (MWA) technology, proudly supported and participated in the 2024 Guangdong Provincial Parathyroid Disease - Southern Yue Forum, held in Guangzhou, China.



This distinguished forum, organized by prominent healthcare institutions in Guangdong, brought together esteemed medical experts, researchers, and healthcare professionals to share insights on advancements in the diagnosis and treatment of parathyroid diseases. The event served as an important platform for academic discussions and the exchange of clinical expertise in the field of endocrine health.

As a sponsor, Baird Medical presented its cutting-edge microwave ablation technology, designed to deliver precise and efficient treatment options for endocrine conditions, including parathyroid diseases. Participants had the opportunity to learn about the company's approach to minimally invasive therapies, aimed at optimizing patient outcomes.

"We are pleased to participate in this highly regarded forum, which reflects our ongoing commitment to supporting medical advancements in endocrine disease management," said Haimei Wu, Chairwoman of Baird Medical. *"Our focus remains on empowering medical professionals with innovative solutions that contribute to improved patient care and clinical outcomes."*

The forum provided Baird Medical with the opportunity to engage with key opinion leaders, foster collaborations, and deepen its understanding of evolving clinical needs. The company's participation underscores its commitment to advancing minimally invasive medical technologies and contributing to the broader healthcare community in a responsible and impactful manner.

About Baird Medical

Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit <https://bairdmed.com/>

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

View original content to download multimedia: <https://www.prnewswire.com/news-releases/baird-medical-showcases-innovations-in-endocrine-care-at-2024-southern-yue-forum-302340100.html>

SOURCE BDMD

Eric Huang, PR Liaison, Baird Medical LLC, Phone: +1 (888) 508-6228, Email: erichuang@bairdmed.com